Comparing Gyre Therapeutics (NASDAQ:GYRE) and Traws Pharma (NASDAQ:TRAW)Defense World · Sep 29, 2026
Gyre Therapeutics to Participate in Upcoming September Investor ConferencesGlobeNewsWire · Sep 3, 2026
Gyre Therapeutics, Inc. (GYRE) Reports Q2 Loss, Beats Revenue EstimatesZacks Investment Research · Aug 7, 2026
Gyre Therapeutics Reports Second Quarter 2026 and Year-to-Date Financial Results and Provides Business UpdateGlobeNewsWire · Aug 7, 2026Gyre Therapeutics, Inc. is a pharmaceutical company dedicated to discovering, advancing, and bringing to market small-molecule drugs that target inflammation and fibrosis in various organs. The company's key anti-fibrotic medication, ETUARY (Pirfenidone), has received approval for treating idiopathic pulmonary fibrosis. Beyond this, ETUARY is also undergoing late-stage (Phase 3) clinical trials for several other conditions, including dermatomyositis and interstitial lung disease linked to systemic sclerosis, pneumoconiosis, and diabetic kidney disease.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 7, 2026 | -$0.06 | -$0.12 | Miss |
| May 7, 2026 | -$0.06 | -$0.05 | Beat |
| Mar 12, 2026 | $0.06 | -$0.02 | Miss |
| Nov 7, 2025 | $0.05 | $0.06 | Beat |
| Aug 11, 2025 | $0.03 | $0.02 | Miss |
| May 9, 2025 | $0.03 | $0.03 | Beat |